TEHP Stock Overview
Operates as a contract development and manufacturing organization for the biotechnology and biopharmaceutical industries in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Avid Bioservices, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.70 |
| 52 Week High | US$11.70 |
| 52 Week Low | US$4.12 |
| Beta | 1.4 |
| 11 Month Change | 22.51% |
| 3 Month Change | 22.51% |
| 1 Year Change | 136.84% |
| 33 Year Change | -56.99% |
| 5 Year Change | 138.78% |
| Change since IPO | -76.12% |
Recent News & Updates
Recent updates
Shareholder Returns
| TEHP | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 4.5% | 0.8% | -1.3% |
| 1Y | 136.8% | -17.5% | 7.4% |
Return vs Industry: TEHP exceeded the German Biotechs industry which returned -17.5% over the past year.
Return vs Market: TEHP exceeded the German Market which returned 7.4% over the past year.
Price Volatility
| TEHP volatility | |
|---|---|
| TEHP Average Weekly Movement | 7.9% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: TEHP's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: TEHP's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 371 | Nick Green | www.avidbio.com |
Avid Bioservices, Inc. operates as a contract development and manufacturing organization for the biotechnology and biopharmaceutical industries in the United States. It provides process development and current good manufacturing practice clinical and commercial manufacturing services of biologics, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, regulatory submission and support, upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization services. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018.
Avid Bioservices, Inc. Fundamentals Summary
| TEHP fundamental statistics | |
|---|---|
| Market cap | €752.36m |
| Earnings (TTM) | -€138.44m |
| Revenue (TTM) | €136.71m |
5.5x
P/S Ratio-5.5x
P/E RatioIs TEHP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TEHP income statement (TTM) | |
|---|---|
| Revenue | US$142.36m |
| Cost of Revenue | US$133.43m |
| Gross Profit | US$8.93m |
| Other Expenses | US$153.10m |
| Earnings | -US$144.16m |
Last Reported Earnings
Jul 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.25 |
| Gross Margin | 6.27% |
| Net Profit Margin | -101.27% |
| Debt/Equity Ratio | 262.4% |
How did TEHP perform over the long term?
See historical performance and comparison